Phillips-Medisize’s Connected Health Platform (CHP) has won Best Innovation in Drug Delivery at the Pharmapack Awards.
Connected health
The company’s unified information-sharing and analytics platform enables pharmaceutical companies to connect medication and diagnostic data across different therapy areas.
CHP provides customisable, scalable medical device data system (MDDS) for pharmaceutical companies and drug delivery device developers.
“We are honoured to be recognised with this award,” said Matt Jennings, CEO and president, Phillips-Medisize. “Phillips-Medisize was at the forefront of connected health solutions with the first FDA approval of a drug-device connected system, BetaConnect. We have taken the experiences gained in regulatory submission, field support, market surveillance, data security and analytics, and patient support from the first-in-market launch and applied them to our latest release, our enterprise-scale, cloud hosted, medical device data system (MDDS) Connected Health Platform. This innovation will allow our customers, the pharmaceutical, diagnostic and device innovators, to rapidly and securely manage the data generated as patients use their products. Through accelerated configuration of a proven MDDS and related components, our customers can now get compliant systems up and running in months, saving significant time and cost as compared to custom or unproven developments. We believe that the Pharmapack Innovation award reinforces our market leading position.”
